Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Brigatinib With Binimetinib in Advanced ALK- or ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)

NCT04005144 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04005144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04005144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Brigatinib With Binimetinib in Advanced ALK- or ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Terminated
Start date
February 25, 2020
Completion date
October 1, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement, lung non-small cell carcinoma, progressive disease, ros1 gene rearrangement, stage iiib lung cancer, stage iiic lung cancer, stage iv lung cancer, stage iva lung cancer, stage ivb lung cancer